secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001628280-23-025916
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q2 revenue drops 28% to $46.1M on HETLIOZ generic erosion
---------------------------------------------------------------

- HETLIOZ net sales $22.0M, down 47% YoY due to at-risk generic launch.
- Net income $1.5M ($0.03 EPS) vs $2.6M ($0.05 EPS) in Q2 2022.
- Fanapt net sales $24.1M, up 4% YoY.
- No 2023 guidance provided; HETLIOZ sales expected to decline further.
- Federal Circuit upheld generic win; Vanda requested rehearing, response due Aug 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023025916/0001628280-23-025916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023025916/vnda-20230727.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-025916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer